经颈静脉肝内门体分流术治疗门静脉高压性顽固性腹水的现状及进展

王宏亮; 张岳林; 王凯冰; 周坦洋; 周官辉; 孙军辉

doi:10.3969/j.issn.1001-5256.2023.07.004

经颈静脉肝内门体分流术治疗门静脉高压性顽固性腹水的现状及进展

DOI: 10.3969/j.issn.1001-5256.2023.07.004

浙江大学医学院附属第一医院肝胆胰介入中心，浙江省肝胆胰疾病临床医学研究中心，浙江省重症肝胆疾病(移植)诊治技术研究中心，杭州 310003

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：王宏亮、张岳林负责查阅文献，起草文章；周坦洋、周官辉负责修改文章；孙军辉负责拟定课题，设计写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
孙军辉，1307005@zju.edu.cn (ORCID：0000-0003-1947-8330)

计量
- 文章访问数: 429
- HTML全文浏览量: 78
- PDF下载量: 121
- 被引次数: 0
出版历程
- 收稿日期: 2023-05-03
- 录用日期: 2023-06-05
- 出版日期: 2023-07-20

Current status and advances in transjugular intrahepatic portosystemic shunt in treatment of refractory ascites due to portal hypertension

Intervention Center of Hepatobiliary and Pancreatic Diseases; Zhejiang Provincial Clinical Medical Research Center of Hepatobiliary and Pancreatic Diseases, Zhejiang Provincial Research Center of Diagnosis and Treatment Techniques for Severe Hepatobiliary Diseases (Transplantation); The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

More Information

Corresponding author: SUN Junhui, 1307005@zju.edu.cn (ORCID: 0000-0003-1947-8330)

摘要

摘要: 顽固性腹水是肝硬化失代偿期门静脉高压的常见并发症之一，预后极差，病死率较高。经颈静脉肝内门体分流术(TIPS)被多项国际及国内指南推荐用于大量腹腔穿刺抽放腹水(LVP)联合输蛋白治疗失败后的治疗方法之一。TIPS可有效控制腹水再发，但有增加肝性脑病的风险，且其是否能延长生存时间仍存在争议。随着对TIPS认识的不断深入、手术技术的成熟、支架材料的更新，迫切需要重新评价TIPS在治疗门静脉高压性顽固性腹水领域中的地位。本文对TIPS治疗门静脉高压性顽固性腹水的现状及进展作一综述。
- 门体分流术, 经颈静脉肝内 /
- 肝硬化 /
- 门静脉高压 /
- 腹水
Abstract: Refractory ascites is one of the common complications of portal hypertension in decompensated liver cirrhosis and is characterized by extremely poor prognosis and high mortality rate. Transjugular intrahepatic portosystemic shunt (TIPS) is recommended by several international and national guidelines as one of the treatment methods after failure of large volume paracentesis combined protein infusion therapy. TIPS can effectively control the recurrence of ascites, but it can increase the risk of hepatic encephalopathy, and there are still controversies over whether it can prolong survival time. With a deeper understanding of TIPS, the maturity of surgical techniques, and the update of stent materials, it is urgent to reevaluate the position of TIPS in the treatment of refractory ascites due to portal hypertension. This article reviews the current status and advances in TIPS for the treatment of refractory ascites due to portal hypertension.
- Portasystemic Shunt, Transjugular Intrahepatic /
- Liver Cirrhosis /
- Portal Hypertension /
- Ascites

HTML全文

参考文献(36)

[1]	LOZANO R, NAGHAVI M, FOREMAN K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2095-2128. DOI: 10.1016/S0140-6736(12)61728-0.
[2]	TSOCHATZIS EA, BOSCH J, BURROUGHS AK. Liver cirrhosis[J]. Lancet, 2014, 383(9930): 1749-1761. DOI: 10.1016/S0140-6736(14)60121-5.
[3]	BLACHIER M, LELEU H, PECK-RADOSAVLJEVIC M, et al. The burden of liver disease in Europe: a review of available epidemiological data[J]. J Hepatol, 2013, 58(3): 593-608. DOI: 10.1016/j.jhep.2012.12.005.
[4]	The Chinese College of Interventionalists. CCI clinical practice guidelines: Management of TIPS for portal hypertension (2019 edition)[J]. J Clin Hepatol, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010. 中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.
[5]	ARROYO V, GINÈS P, GERBES AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club[J]. Hepatology, 1996, 23(1): 164-176. DOI: 10.1002/hep.510230122.
[6]	European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J]. J Hepatol, 2010, 53(3): 397-417. DOI: 10.1016/j.jhep.2010.05.004.
[7]	BIGGINS SW, ANGELI P, GARCIA-TSAO G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 74(2): 1014-1048. DOI: 10.1002/hep.31884.
[8]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003. 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.
[9]	WANG LJ, YAO X, QIN JP, et al. TIPS for treatment of refractory ascites in cirrhosis[J]. J Clin Hepatol, 2022, 38(11): 2606-2610. DOI: 10.3969/j.issn.1001-5256.2022.11.034. 王澜静, 姚欣, 秦建平, 等. 经颈静脉肝内门体分流术治疗肝硬化顽固性腹水的现状[J]. 临床肝胆病杂志, 2022, 38(11): 2606-2610. DOI: 10.3969/j.issn.1001-5256.2022.11.034.
[10]	WANG SZ, DING HG. New therapeutic paradigm and concepts for patients with cirrhotic refractory ascites[J]. Chin J Hepatol, 2017, 25(4): 249-253. DOI: 10.3760/cma.j.issn.1007-3418.2017.04.003. 王淑珍, 丁惠国. 肝硬化顽固性腹水新的治疗模式及理念[J]. 中华肝脏病杂志, 2017, 25(4): 249-253. DOI: 10.3760/cma.j.issn.1007-3418.2017.04.003.
[11]	MORALI GA, SNIDERMAN KW, DEITEL KM, et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?[J]. J Hepatol, 1992, 16(1-2): 249-250. DOI: 10.1016/s0168-8278(05)80128-x.
[12]	CASADO M, BOSCH J, GARCÍA-PAGÁN JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings[J]. Gastroenterology, 1998, 114(6): 1296-1303. DOI: 10.1016/s0016-5085(98)70436-6.
[13]	IWAKIRI Y, GROSZMANN RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule[J]. Hepatology, 2006, 43(2 Suppl 1): S121-S131. DOI: 10.1002/hep.20993.
[14]	SCHRIER RW, ARROYO V, BERNARDI M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis[J]. Hepatology, 1988, 8(5): 1151-1157. DOI: 10.1002/hep.1840080532.
[15]	CÁRDENAS A, ARROYO V. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites[J]. Best Pract Res Clin Endocrinol Metab, 2003, 17(4): 607-622. DOI: 10.1016/s1521-690x(03)00052-6.
[16]	BERNARDI M, MOREAU R, ANGELI P, et al. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis[J]. J Hepatol, 2015, 63(5): 1272-1284. DOI: 10.1016/j.jhep.2015.07.004.
[17]	BOIKE JR, THORNBURG BG, ASRANI SK, et al. North american practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension[J]. Clin Gastroenterol Hepatol, 2022, 20(8): 1636-1662. e36. DOI: 10.1016/j.cgh.2021.07.018.
[18]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VⅡ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[19]	LEBREC D, GIUILY N, HADENGUE A, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists[J]. J Hepatol, 1996, 25(2): 135-144. DOI: 10.1016/s0168-8278(96)80065-1.
[20]	RÖSSLE M, OCHS A, GVLBERG V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites[J]. N Engl J Med, 2000, 342(23): 1701-1707. DOI: 10.1056/NEJM200006083422303.
[21]	GINÈS P, URIZ J, CALAHORRA B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis[J]. Gastroenterology, 2002, 123(6): 1839-1847. DOI: 10.1053/gast.2002.37073.
[22]	SANYAL AJ, GENNING C, REDDY KR, et al. The North American Study for the treatment of refractory ascites[J]. Gastroenterology, 2003, 124(3): 634-641. DOI: 10.1053/gast.2003.50088.
[23]	SALERNO F, MERLI M, RIGGIO O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites[J]. Hepatology, 2004, 40(3): 629-635. DOI: 10.1002/hep.20364.
[24]	NARAHARA Y, KANAZAWA H, FUKUDA T, et al. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial[J]. J Gastroenterol, 2011, 46(1): 78-85. DOI: 10.1007/s00535-010-0282-9.
[25]	BUREAU C, THABUT D, OBERTI F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites[J]. Gastroenterology, 2017, 152(1): 157-163. DOI: 10.1053/j.gastro.2016.09.016.
[26]	PERARNAU JM, LE GOUGE A, NICOLAS C, et al. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial[J]. J Hepatol, 2014, 60(5): 962-968. DOI: 10.1016/j.jhep.2014.01.015.
[27]	BAI M, QI XS, YANG ZP, et al. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis[J]. World J Gastroenterol, 2014, 20(10): 2704-2714. DOI: 10.3748/wjg.v20.i10.2704.
[28]	CHEN RP, ZHU GE XJ, HUANG ZM, et al. Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites: metaregression and trial sequential meta-analysis[J]. J Clin Gastroenterol, 2014, 48(3): 290-299. DOI: 10.1097/MCG.0b013e3182a115e9.
[29]	WANG Q, LV Y, BAI M, et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding[J]. J Hepatol, 2017, 67(3): 508-516. DOI: 10.1016/j.jhep.2017.05.006.
[30]	MIRAGLIA R, MARUZZELLI L, TUZZOLINO F, et al. Transjugular intrahepatic portosystemic shunts in patients with cirrhosis with refractory ascites: comparison of clinical outcomes by using 8- and 10-mm PTFE-covered stents[J]. Radiology, 2017, 284(1): 281-288. DOI: 10.1148/radiol.2017161644.
[31]	TREBICKA J, BASTGEN D, BYRTUS J, et al. Smaller-diameter covered transjugular intrahepatic portosystemic shunt stents are associated with increased survival[J]. Clin Gastroenterol Hepatol, 2019, 17(13): 2793-2799. e1. DOI: 10.1016/j.cgh.2019.03.042.
[32]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024.
[33]	BERCU ZL, FISCHMAN AM, KIM E, et al. TIPS for refractory ascites: a 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts[J]. AJR Am J Roentgenol, 2015, 204(3): 654-661. DOI: 10.2214/AJR.14.12885.
[34]	BUREAU C, MÉTIVIER S, D'AMICO M, et al. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS[J]. J Hepatol, 2011, 54(5): 901-907. DOI: 10.1016/j.jhep.2010.08.025.
[35]	NARDELLI S, LATTANZI B, TORRISI S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement[J]. Clin Gastroenterol Hepatol, 2017, 15(6): 934-936. DOI: 10.1016/j.cgh.2016.10.028.
[36]	BENMASSAOUD A, ROCCARINA D, ARICO F, et al. Sarcopenia does not worsen survival in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt for refractory ascites[J]. Am J Gastroenterol, 2020, 115(11): 1911-1914. DOI: 10.14309/ajg.0000000000000959.